Expression of COX-1, COX-2, 5-LOX and $$\hbox {CysLT}_2$$ CysLT2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease

Abstract Background Aspirin exacerbated respiratory disease (AERD) is a disease of the upper and lower airways. It is characterized by severe asthma, chronic sinusitis with nasal polyps (CRSwNP) and intolerance towards nonsteroidal analgesics (NSAR). Arachidonic acid (AA) metabolites play an importa...

Full description

Bibliographic Details
Main Authors: Monique Vorsprach, Christoph Arens, Stephan Knipping, Dörte Jechorek, Sabine Stegemann-Koniszewski, Eva Lücke, Jens Schreiber
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Online Access:https://doi.org/10.1186/s13223-019-0395-5
_version_ 1818611494542114816
author Monique Vorsprach
Christoph Arens
Stephan Knipping
Dörte Jechorek
Sabine Stegemann-Koniszewski
Eva Lücke
Jens Schreiber
author_facet Monique Vorsprach
Christoph Arens
Stephan Knipping
Dörte Jechorek
Sabine Stegemann-Koniszewski
Eva Lücke
Jens Schreiber
author_sort Monique Vorsprach
collection DOAJ
description Abstract Background Aspirin exacerbated respiratory disease (AERD) is a disease of the upper and lower airways. It is characterized by severe asthma, chronic sinusitis with nasal polyps (CRSwNP) and intolerance towards nonsteroidal analgesics (NSAR). Arachidonic acid (AA) metabolites play an important role in the pathogenesis of AERD. It is still unknown, whether metabolism of AA is comparable between the upper and lower airways as well as between patients with and without NSAR intolerance. Objective We sought to analyze differences in the expression of cyclooxygenases type 1 and 2 (COX-1, COX-2), arachidonate 5-lipoxygenase (5-LOX) and cysteinyl leukotriene receptor type 2 ($$\hbox {CysLT}_2$$ CysLT2 ) in nasal polyps and the bronchial mucosa of patients with aspirin intolerant asthma (AIA, $$n=23$$ n=23 ) as compared to patients with aspirin tolerant asthma (ATA, $$n=17$$ n=17 ) and a control group with nasal polyps, but without asthma (NPwA, $$n=15$$ n=15 ). Methods Tissue biopsies from nasal polyps and bronchial mucosa were obtained during surgical treatment of nasal polyps by endonasal functional endoscopic sinus surgery (FESS) under general anesthesia from intubated patients. Immunohistochemistry was used to analyze the expression of COX-1, COX-2, 5-LOX and $$\hbox {CysLT}_2$$ CysLT2 in nasal and bronchial mucosa. Categorization into the different patient groups was performed according to the patient history, clinical and laboratory data, pulmonary function and provocation tests, as well as allergy testing. Results We observed a stronger expression of 5-LOX and $$\hbox {CysLT}_2$$ CysLT2 in submucosal glands of nasal and bronchial tissue compared to epithelial expression. The expression of COX-1 and COX-2 was stronger in epithelia compared to submucosal glands. There was a similar expression of the enzymes and $$\hbox {CysLT}_2$$ CysLT2 between upper and lower airways in all patient groups. We did not detect any significant differences between the patient groups. Conclusions The AA-metabolizing enzymes and the $$\hbox {CysLT}_2$$ CysLT2 were expressed in a very similar way in different microscopic structures in samples of the upper and lower airways of individual patients. We did not detect differences between the patient groups indicating the pathogenetic role of AA metabolism in these disorders is independent of the presence of NSAR-intolerance.
first_indexed 2024-12-16T15:31:13Z
format Article
id doaj.art-9e7bed16904f4bf9931d1163b9ac3223
institution Directory Open Access Journal
issn 1710-1492
language English
last_indexed 2024-12-16T15:31:13Z
publishDate 2019-12-01
publisher BMC
record_format Article
series Allergy, Asthma & Clinical Immunology
spelling doaj.art-9e7bed16904f4bf9931d1163b9ac32232022-12-21T22:26:21ZengBMCAllergy, Asthma & Clinical Immunology1710-14922019-12-0115111410.1186/s13223-019-0395-5Expression of COX-1, COX-2, 5-LOX and $$\hbox {CysLT}_2$$ CysLT2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway diseaseMonique Vorsprach0Christoph Arens1Stephan Knipping2Dörte Jechorek3Sabine Stegemann-Koniszewski4Eva Lücke5Jens Schreiber6Departmemt of Pneumology, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-UniversityDepartment of Otorhinolaryngology, Head- and Neck Surgery, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-UniversityDepartment of Otorhinolaryngology, Head- and Neck Surgery, Plastical Surgery, Dessau Medical Center, Martin-Luther-University HalleDepartment of Pathology, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-UniversityDepartmemt of Pneumology, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-UniversityDepartmemt of Pneumology, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-UniversityDepartmemt of Pneumology, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-UniversityAbstract Background Aspirin exacerbated respiratory disease (AERD) is a disease of the upper and lower airways. It is characterized by severe asthma, chronic sinusitis with nasal polyps (CRSwNP) and intolerance towards nonsteroidal analgesics (NSAR). Arachidonic acid (AA) metabolites play an important role in the pathogenesis of AERD. It is still unknown, whether metabolism of AA is comparable between the upper and lower airways as well as between patients with and without NSAR intolerance. Objective We sought to analyze differences in the expression of cyclooxygenases type 1 and 2 (COX-1, COX-2), arachidonate 5-lipoxygenase (5-LOX) and cysteinyl leukotriene receptor type 2 ($$\hbox {CysLT}_2$$ CysLT2 ) in nasal polyps and the bronchial mucosa of patients with aspirin intolerant asthma (AIA, $$n=23$$ n=23 ) as compared to patients with aspirin tolerant asthma (ATA, $$n=17$$ n=17 ) and a control group with nasal polyps, but without asthma (NPwA, $$n=15$$ n=15 ). Methods Tissue biopsies from nasal polyps and bronchial mucosa were obtained during surgical treatment of nasal polyps by endonasal functional endoscopic sinus surgery (FESS) under general anesthesia from intubated patients. Immunohistochemistry was used to analyze the expression of COX-1, COX-2, 5-LOX and $$\hbox {CysLT}_2$$ CysLT2 in nasal and bronchial mucosa. Categorization into the different patient groups was performed according to the patient history, clinical and laboratory data, pulmonary function and provocation tests, as well as allergy testing. Results We observed a stronger expression of 5-LOX and $$\hbox {CysLT}_2$$ CysLT2 in submucosal glands of nasal and bronchial tissue compared to epithelial expression. The expression of COX-1 and COX-2 was stronger in epithelia compared to submucosal glands. There was a similar expression of the enzymes and $$\hbox {CysLT}_2$$ CysLT2 between upper and lower airways in all patient groups. We did not detect any significant differences between the patient groups. Conclusions The AA-metabolizing enzymes and the $$\hbox {CysLT}_2$$ CysLT2 were expressed in a very similar way in different microscopic structures in samples of the upper and lower airways of individual patients. We did not detect differences between the patient groups indicating the pathogenetic role of AA metabolism in these disorders is independent of the presence of NSAR-intolerance.https://doi.org/10.1186/s13223-019-0395-5AsthmaNasal polypsAspirin exacerbated respiratory diseaseArachidonic acidCyclooxygenasesLipoxygenases
spellingShingle Monique Vorsprach
Christoph Arens
Stephan Knipping
Dörte Jechorek
Sabine Stegemann-Koniszewski
Eva Lücke
Jens Schreiber
Expression of COX-1, COX-2, 5-LOX and $$\hbox {CysLT}_2$$ CysLT2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease
Allergy, Asthma & Clinical Immunology
Asthma
Nasal polyps
Aspirin exacerbated respiratory disease
Arachidonic acid
Cyclooxygenases
Lipoxygenases
title Expression of COX-1, COX-2, 5-LOX and $$\hbox {CysLT}_2$$ CysLT2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease
title_full Expression of COX-1, COX-2, 5-LOX and $$\hbox {CysLT}_2$$ CysLT2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease
title_fullStr Expression of COX-1, COX-2, 5-LOX and $$\hbox {CysLT}_2$$ CysLT2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease
title_full_unstemmed Expression of COX-1, COX-2, 5-LOX and $$\hbox {CysLT}_2$$ CysLT2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease
title_short Expression of COX-1, COX-2, 5-LOX and $$\hbox {CysLT}_2$$ CysLT2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease
title_sort expression of cox 1 cox 2 5 lox and hbox cyslt 2 cyslt2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease
topic Asthma
Nasal polyps
Aspirin exacerbated respiratory disease
Arachidonic acid
Cyclooxygenases
Lipoxygenases
url https://doi.org/10.1186/s13223-019-0395-5
work_keys_str_mv AT moniquevorsprach expressionofcox1cox25loxandhboxcyslt2cyslt2innasalpolypsandbronchialtissueofpatientswithaspirinexacerbatedairwaydisease
AT christopharens expressionofcox1cox25loxandhboxcyslt2cyslt2innasalpolypsandbronchialtissueofpatientswithaspirinexacerbatedairwaydisease
AT stephanknipping expressionofcox1cox25loxandhboxcyslt2cyslt2innasalpolypsandbronchialtissueofpatientswithaspirinexacerbatedairwaydisease
AT dortejechorek expressionofcox1cox25loxandhboxcyslt2cyslt2innasalpolypsandbronchialtissueofpatientswithaspirinexacerbatedairwaydisease
AT sabinestegemannkoniszewski expressionofcox1cox25loxandhboxcyslt2cyslt2innasalpolypsandbronchialtissueofpatientswithaspirinexacerbatedairwaydisease
AT evalucke expressionofcox1cox25loxandhboxcyslt2cyslt2innasalpolypsandbronchialtissueofpatientswithaspirinexacerbatedairwaydisease
AT jensschreiber expressionofcox1cox25loxandhboxcyslt2cyslt2innasalpolypsandbronchialtissueofpatientswithaspirinexacerbatedairwaydisease